Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $47
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
Barclays analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $42 to $47.
Barclays analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $42 to $47.